Global Gene Editing Therapeutics Market Strategic Research Report

The global gene editing therapeutics market — encompassing CRISPR-Cas9, base editing, and prime editing platforms — represented approximately USD 7.4 billion in 2024, positioned at the intersection of molecular biology, clinical medicine, and advanced manufacturing. This market has transitioned from purely academic research settings into a commercially active arena, with the first CRISPR-based therapies receiving regulatory approvals in late 2023 and early 2024, marking a structural inflection point for the entire sector. The ability to precisely modify, correct, or silence specific genomic sequences offers a fundamentally different therapeutic modality compared with conventional small molecules or biologics, driving institutional capital and pharmaceutical partnership activity to levels not previously seen in this segment of biotechnology.

Three converging forces are propelling sustained market expansion. First, the accelerating clinical validation of CRISPR-Cas9 in haematological disorders — most notably sickle cell disease and transfusion-dependent beta-thalassemia — has established proof-of-concept across a gene correction paradigm that is now being extended to oncology, ophthalmology, and metabolic disease indications. Second, the emergence of next-generation base editing and prime editing tools materially reduces the risk of double-strand DNA breaks and unintended off-target modifications, broadening the addressable patient population and facilitating regulatory acceptance in previously inaccessible indication areas. Third, advances in lipid nanoparticle and adeno-associated virus delivery systems have resolved a longstanding bottleneck in systemic in vivo editing, enabling therapeutic concentrations in tissues beyond ex vivo-accessible haematopoietic stem cells. The principal restraint on near-term growth is the extraordinary cost of goods and patient-level pricing — exemplified by therapies priced in excess of USD 2 million per patient — which creates reimbursement uncertainty across both mature and emerging healthcare markets.

This report provides a comprehensive, data-anchored analysis of the global gene editing therapeutics market across the 2025–2032 forecast period, with a 2024 base year and historical review extending to 2019. Coverage spans all major editing modalities, therapeutic applications, regional markets, and competitive dynamics, including detailed profiles of ten leading companies. The report is designed to serve corporate strategy teams evaluating pipeline investments, investment analysts modelling sector returns, M&A advisors assessing platform acquisition targets, and procurement managers within health systems preparing for high-cost cell and gene therapy integration.